Integrated Filing — IndAS



General information about company
Scrip Code 532612
NSE Symbol INDOCO
MSEI Symbol NOTLISTED
ISIN INE873D01024
Name of company INDOCO REMEDIES LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2025
Date of end of financial year 31-Mar-2026
Date of board meeting when results were approved 24-Jul-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 14-Jul-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Single segment
Description of single segment Pharmaceutical
Start date and time of board meeting 24-Jul-2025   10:30:00
End date and time of board meeting 24-Jul-2025   11:50:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 4378900000
Other income 16300000
Total income 4395200000
2 Expenses
(a) Cost of materials consumed 1055300000
(b) Purchases of stock-in-trade 392300000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -97900000
(d) Employee benefit expense 1070200000
(e) Finance costs 261200000
(f) Depreciation, depletion and amortisation expense 297000000
(f) Other Expenses
1 RESEARCH & DEVELOPMENT EXPENSES 216600000 216600000
2 OTHER EXPENSES 1567100000 1567100000
Total other expenses 1783700000
Total expenses 4761800000
3 Total profit before exceptional items and tax -366600000
4 Exceptional items 0
5 Total profit before tax -366600000
6 Tax expense
7 Current tax 0
8 Deferred tax -3100000
9 Total tax expenses -3100000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0
11 Net Profit Loss for the period from continuing operations -363500000
12 Profit (loss) from discontinued operations before tax 0
13 Tax expense of discontinued operations 0
14 Net profit (loss) from discontinued operation after tax 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0
16 Total profit (loss) for period -363500000
17 Other comprehensive income net of taxes -1600000
18 Total Comprehensive Income for the period -365100000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent -357900000
Total profit or loss, attributable to non-controlling interests -5600000
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent -359500000
Total comprehensive income for the period attributable to owners of parent non-controlling interests -5600000
21 Details of equity share capital
Paid-up equity share capital 184500000
Face value of equity share capital 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations -3.94
Diluted earnings (loss) per share from continuing operations -3.94
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0
Diluted earnings (loss) per share from discontinued operations 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations -3.94
Diluted earnings (loss) per share from continuing and discontinued operations -3.94
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results
Textual Information(1) 1. The unaudited Consolidated Results for the Quarter ended 30th June, 2025, have been reviewed by the Audit committee and approved by the Board of Directors of the Company at its meeting held on 24th July, 2025. The Statutory Auditors have expressed an Unmodified Audit opinion on these unaudited Consolidated Financial Results. n n2. The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable. n n3. The company has only one primary reportable segment of activity, namely, Pharmaceuticals. n n4. Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows: n nNet Sales Qtr ended Qtr ended Qtr ended Year ended n& Income 30-06-2025 31-03-2025 30-06-2024 31-03-2025 nfrom Operations (Unaudited) (Audited) (Unaudited) (Audited) n nIndia 27,783 26,186 25,675 1,09,039 nOutside India 15,125 12,203 16,754 55,090 --------------------------------------------------------------------------------------------------------------------------- nTotal : 42,908 38,389 42,429 1,64,129============================================================== n n5. The Consolidated Financial Results includes the results of the following companies. n----------------------------------------------------------------------------------------------------------------------------- nName of the Company % of shareholding Consolidated as n------------------------------------------------------------------------------------------------------------------------------ nXTEND INDUSTRIAL DESIGNERS 100.00 SUBSIDIARY n& ENGINEERS PVT LTD nINDOCO REMEDIES CZECH SRO 100.00 SUBSIDIARY nINDOCO REMEDIES UK LTD 100.00 SUBSIDIARY nWARREN REMEDIES PVT LTD 100.00 SUBSIDIARY nFPP HOLDING COMPANY ,LLC 85.00 SUBSIDIARY n-------------------------------------------------------------------------------------------------------------------------- n n6. Figures for the quarter ended 31.3.2025 and 31.3.2024 represents the difference between audited figures in respect of the full financial year and published figures for the period ended 31.12.2024 (limited reviewed) and 31.12.2023 (limited reviewed). n n7. (*) Exceptional items include consideration received Rs. 99.4 lacs for grants to use exclusive, perpetual and irrevocable license rights in respect of trademarks of the company. n



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2025
Date of end of reporting period 30-Jun-2025
Whether accounts are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to profit & loss -7700000 -7700000
Total Amount of items that will not be reclassified to profit and loss -7700000
2 Income tax relating to items that will not be reclassified to profit or loss -1900000
3 Amount of items that will be reclassified to profit and loss
1 Items that may be reclassified to profit or loss 8700000 8700000
Total Amount of items that will be reclassified to profit and loss 8700000
4 Income tax relating to items that will be reclassified to profit or loss 4500000
5 Total Other comprehensive income -1600000





Details of Impact of Audit Qualification
Whether results are audited or unaudited
Declaration of unmodified opinion or statement on impact of audit qualification
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto